Hepatic Safety Profile of Vildagliptin 100 mg SR - Ft. Prof. Dr Aravinda Jagadeesha

Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-11-26 07:03 GMT   |   Update On 2023-05-03 07:31 GMT

Vildagliptin has established its efficacy over the years by displaying significant HbA1c lowering accompanied by body weight-neutral and lipid-neutral effects, low risk of edema, and low risk of hypoglycemia. These characteristics make vildagliptin a favorable partner for combination therapy as well as newer formulations like sustained release.
Several studies have also focussed on establishing safety parameters of Vildagliptin.
In this video, Prof. Dr Aravinda Jagadeesha, a diabetologist and the chairman at Dr Aravind's Diabetes Centre in Bengaluru, India talks about how Vildagliptin as a molecule has proven itself in the past 15 years and provides his insights on the hepatic safety profile of Vildagliptin 100mg SR.
Dr Jagadeesha specifically alludes to a pooled hepatic safety analysis, in which it was seen that there was no overall increased risk of persistent transaminase elevations with concomitant bilirubin elevation greater than the upper limit for either vildagliptin dose.
Full View
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News